Using cue reactivity to evaluate medications for treatment of cocaine dependence: a critical review. 1999

V Modesto-Lowe, and H R Kranzler
Alcohol Research Center, Department of Psychiatry, University of Connecticut School of Medicine, Farmington 06030-2103, USA. modesto@psychiatry.uchc.edu

OBJECTIVE The aim of this article is to examine the validity of a cue-reactivity paradigm for evaluating medications to treat cocaine dependence and to critically review cocaine pharmacotherapy studies that use this method. METHODS A Medline computerized search was performed to identify randomized, controlled medication studies for cocaine dependence that employed a cue-reactivity paradigm. Relevant bibliographies of these articles were also reviewed. Eleven placebo-controlled studies were identified in the English language literature. Four of these studies used agents that block dopaminergic neurotransmission, two studies used agents that modify the serotonergic system, and two studies used nicotinergic agents. The other three studies employed a mood stabilizer, an opioid antagonist or a psychostimulant. RESULTS There has been little research examining the theoretical basis of the cue-reactivity model, as applied to the screening of medications to treat cocaine dependence. From a methodological viewpoint, most studies have shown that exposure to cocaine-related stimuli increases subjective and physiological reactivity in cocaine-dependent patients, but methods used to present the cues and to measure cue reactivity have not been consistent across studies. Similarly, the observed increase in subjective and physiological reactivity to cocaine cues has varied within and across studies. CONCLUSIONS If a cocaine cue-reactivity paradigm is to be used to evaluate medications for treatment of cocaine dependence, the validity of the model must first be demonstrated and a consistent methodology for cue presentation and measurement of responses must be developed.

UI MeSH Term Description Entries
D009292 Narcotic Antagonists Agents inhibiting the effect of narcotics on the central nervous system. Competitive Opioid Antagonist,Narcotic Antagonist,Opioid Antagonist,Opioid Antagonists,Opioid Receptor Antagonist,Opioid Reversal Agent,Competitive Opioid Antagonists,Opioid Receptor Antagonists,Opioid Reversal Agents,Agent, Opioid Reversal,Agents, Opioid Reversal,Antagonist, Competitive Opioid,Antagonist, Narcotic,Antagonist, Opioid,Antagonist, Opioid Receptor,Antagonists, Competitive Opioid,Antagonists, Narcotic,Antagonists, Opioid,Antagonists, Opioid Receptor,Opioid Antagonist, Competitive,Opioid Antagonists, Competitive,Receptor Antagonist, Opioid,Receptor Antagonists, Opioid,Reversal Agent, Opioid,Reversal Agents, Opioid
D003463 Cues Signals for an action; that specific portion of a perceptual field or pattern of stimuli to which a subject has learned to respond. Cue
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D018490 Serotonin Agents Drugs used for their effects on serotonergic systems. Among these are drugs that affect serotonin receptors, the life cycle of serotonin, and the survival of serotonergic neurons. Serotonergic Agents,Serotonergic Drugs,Serotonin Drugs,Serotonin Effect,Serotonin Effects,Serotoninergic Effect,Serotoninergic Effects,Agents, Serotonergic,Agents, Serotonin,Drugs, Serotonergic,Drugs, Serotonin,Effect, Serotonin,Effect, Serotoninergic,Effects, Serotonin,Effects, Serotoninergic
D018491 Dopamine Agonists Drugs that bind to and activate dopamine receptors. Dopamine Receptor Agonists,Dopaminergic Agonists,Agonists, Dopamine Receptor,Agonists, Dopaminergic,Dopamine Agonist,Dopamine Receptor Agonist,Dopaminergic Agonist,Receptor Agonists, Dopamine,Agonist, Dopamine,Agonist, Dopamine Receptor,Agonist, Dopaminergic,Agonists, Dopamine,Receptor Agonist, Dopamine
D018492 Dopamine Antagonists Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. Dopamine Antagonist,Dopamine Blocker,Dopamine Receptor Antagonist,Dopamine Receptor Antagonists,Dopaminergic Antagonist,Dopaminergic Antagonists,Antagonists, Dopamine,Antagonists, Dopamine Receptor,Antagonists, Dopaminergic,Dopamine Blockers,Antagonist, Dopamine,Antagonist, Dopamine Receptor,Antagonist, Dopaminergic,Blocker, Dopamine,Blockers, Dopamine,Receptor Antagonist, Dopamine,Receptor Antagonists, Dopamine
D018678 Cholinergic Agents Any drug used for its actions on cholinergic systems. Included here are agonists and antagonists, drugs that affect the life cycle of ACETYLCHOLINE, and drugs that affect the survival of cholinergic neurons. The term cholinergic agents is sometimes still used in the narrower sense of MUSCARINIC AGONISTS, although most modern texts discourage that usage. Acetylcholine Agent,Acetylcholine Agents,Cholinergic,Cholinergic Agent,Cholinergic Drug,Cholinomimetic,Cholinomimetics,Muscarinic,Muscarinic Agent,Muscarinic Agents,Nicotinic Agent,Nicotinic Agents,Cholinergic Drugs,Cholinergic Effect,Cholinergic Effects,Cholinergics,Muscarinic Effect,Muscarinic Effects,Muscarinics,Nicotinic Effect,Nicotinic Effects,Agent, Acetylcholine,Agent, Cholinergic,Agent, Muscarinic,Agent, Nicotinic,Agents, Acetylcholine,Agents, Cholinergic,Agents, Muscarinic,Agents, Nicotinic,Drug, Cholinergic,Drugs, Cholinergic,Effect, Cholinergic,Effect, Muscarinic,Effect, Nicotinic,Effects, Cholinergic,Effects, Muscarinic,Effects, Nicotinic
D019964 Mood Disorders Those disorders that have a disturbance in mood as their predominant feature. Affective Disorders,Affective Disorder,Disorder, Affective,Disorder, Mood,Disorders, Affective,Disorders, Mood,Mood Disorder

Related Publications

V Modesto-Lowe, and H R Kranzler
January 1992, Addictive behaviors,
V Modesto-Lowe, and H R Kranzler
May 2011, Recent patents on CNS drug discovery,
V Modesto-Lowe, and H R Kranzler
January 2009, Annali dell'Istituto superiore di sanita,
V Modesto-Lowe, and H R Kranzler
January 1997, NIDA research monograph,
V Modesto-Lowe, and H R Kranzler
December 2005, Psychiatry (Edgmont (Pa. : Township)),
V Modesto-Lowe, and H R Kranzler
June 2009, Drug and alcohol dependence,
V Modesto-Lowe, and H R Kranzler
July 2007, The Cochrane database of systematic reviews,
V Modesto-Lowe, and H R Kranzler
March 2016, The Cochrane database of systematic reviews,
V Modesto-Lowe, and H R Kranzler
January 1993, NIDA research monograph,
V Modesto-Lowe, and H R Kranzler
October 1995, Drug and alcohol dependence,
Copied contents to your clipboard!